Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable but only when programs are designed with precision and foresight.
-
1 Posts
-
1 Photos
-
0 Videos
-
Female
-
Followed by 9 people
Search
Friends
29
